NEW YORK (GenomeWeb) — Regulus Therapeutics this week released interim results from an ongoing Phase I study of its microRNA-targeting hepatitis C therapy RG-101, which showed that a single subcutaneous dose of the drug could trigger an average 4.1-log reduction in viral loads in patients — a number on par with current treatments.

On the better-than-expected data, shares of Regulus rocketed up more than 115 percent, hitting $14.60 during Wednesday afternoon trading on the Nasdaq.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.